Abstract
Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials.
Original language | English (US) |
---|---|
Pages (from-to) | 625-632 |
Number of pages | 8 |
Journal | Gynecologic oncology |
Volume | 160 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2021 |
Keywords
- Gynecologic cancers
- Lymphedema
- Oncologic surgical treatment
- Patient reported outcomes
- Quantitative measurements
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology